Project no.: HIV-NAT 006
Brief summary: This is a long-term, post study cohort of HIV-infected patients who previously participated in HIV-NAT study protocols. Information collected from this cohort will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approaches, efficacy of HIV viral load and CD4 cell counts as predictors of disease progression, mortality, resistance profiles, adherence, immune recovery syndrome, opportunistic infections or malignancies, incidence of lipodystrophy, other metabolic complications, cardiovascular, renal, hepatic, and endocrine function, skin, gastrointestinal system and urogenital tract problems and quality of life.
21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014 at Boston, USA
Avihingsanon A, Jitmitraparp S, Sapsirisavat V, Apornpong T, Mengthisong T, Kerr S, Matthews GV, Lewin SR, Ruxrungtham Kand the HIV-NAT 006 study team. Liver fibrosis is not uncommon in HIV-infected patients without viral or alcoholic hepatitis. Oral presentation.
16th International Congress on Infectious Diseases (ICID), 2-5 April 2014 at Cape Town, South Africa
AvihingsanonA, Maek-a-nantawat W, Mansawat T, Moonthong K, Chaiya O, Phonphithak S, Ruxrungtham Kon behalf of HIV-NAT 006 study group. Sexually transmitted infections among HIV-infected individuals on antiretroviral therapy.
Avihingsanon A, Apornpong T, Kerr SJ, Make-a-nantawat W, Thammajaruk N,Phonphithak S, Ramautarsing RA, Clarke A, Phanuphak P, Burger DM, Ruxrungtham Rand HIV-NAT 006 study team. Low Dose Ritonavir-Boosted Atazanavir (200/100 mg) maintained high virological efficacy up to 4 years in treatment-experienced HIV-1 Infected Adults: A prospective cohort study from Asia. J AIDS Clin Res 2015;6:477.